# OnCo record t-cell-exhaustion (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/t-cell-exhaustion/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "t-cell-exhaustion" ;
  schema:name "T-cell exhaustion"@en ;
  schema:description "T cells that see their target for weeks on end without winning gradually shut down: they raise a set of brakes (PD-1, LAG-3, TIM-3, TIGIT), lose their ability to kill, and eventually lock this state into their DNA. Checkpoint drugs rescue the ones that are only partly exhausted; the terminally exhausted are beyond reach."@en ;
  schema:url <https://onco.cc/pathways/t-cell-exhaustion/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/T_cell_exhaustion> ;
  schema:citation <https://doi.org/10.1038/nri3862> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/til-therapy/>, <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/armored-car/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/tigit/>, <https://onco.cc/targets/tim3/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/relatlimab-nivolumab/>, <https://onco.cc/drugs/fianlimab/>, <https://onco.cc/drugs/tiragolumab/>, <https://onco.cc/drugs/nogapendekin-alfa/>, <https://onco.cc/drugs/bempegaldesleukin/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/pathways/epigenetic-reprogramming/> ;
  onco:terms <https://onco.cc/terms/tils/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/avoiding-immune-destruction/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-wherry-nat-rev-immunol/> .